Efficacy of Topical Gentamycin for Hereditary Hypotrichosis Simplex Caused by Nonsense Mutations in CDSN
Status:
Unknown status
Trial end date:
2019-04-01
Target enrollment:
Participant gender:
Summary
The scalp-limited for of hereditary hypotrichosis simplex (HHS; MIM146520) is an autosomal
dominant form of non-syndromic alopecia which is caused by heterozygous nonsense mutations in
the CDSN gene, encoding corneodesmosin (1). The disease features diffuse gradual scalp hair
loss that starts in the middle of the first decade of life and progresses to total alopecia
till the third decade of life. Recent studies have shown that aminoglycosides have the
potential to induce readthrough of nonsense mutations in human cells.
The aim of this study is to investigate whether topical aminoglycosides (Gentamycin) may be
beneficial for the treatment of HHS patients carrying nonsense mutations by inducing
readthrough.
The Study goals:
To assess the short and long term efficacy of topical gentamycin for the treatment of
hereditary hypotrichosis simplex caused by nonsense heterozygous mutations in CDSN.
The primary end point:
To assess scalp hair growth during study period as compared to baseline. Hair growth will be
evaluated during enrollment and every 4 weeks. The secondary end points will be time to
regrowth for determining efficacy.